GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioinfra Co Ltd (XKRX:199730) » Definitions » Debt-to-EBITDA

Bioinfra Co (XKRX:199730) Debt-to-EBITDA : -9.99 (As of Sep. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Bioinfra Co Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bioinfra Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₩4,432 Mil. Bioinfra Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2024 was ₩4,310 Mil. Bioinfra Co's annualized EBITDA for the quarter that ended in Sep. 2024 was ₩-875 Mil. Bioinfra Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 was -9.99.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Bioinfra Co's Debt-to-EBITDA or its related term are showing as below:

XKRX:199730' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0.91   Med: 1.71   Max: 29.83
Current: 29.83

During the past 4 years, the highest Debt-to-EBITDA Ratio of Bioinfra Co was 29.83. The lowest was 0.91. And the median was 1.71.

XKRX:199730's Debt-to-EBITDA is ranked worse than
95.47% of 265 companies
in the Biotechnology industry
Industry Median: 1.52 vs XKRX:199730: 29.83

Bioinfra Co Debt-to-EBITDA Historical Data

The historical data trend for Bioinfra Co's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioinfra Co Debt-to-EBITDA Chart

Bioinfra Co Annual Data
Trend Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
1.66 1.77 0.91 2.20

Bioinfra Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.28 1.38 -3.10 -5.20 -9.99

Competitive Comparison of Bioinfra Co's Debt-to-EBITDA

For the Biotechnology subindustry, Bioinfra Co's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Bioinfra Co's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioinfra Co's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Bioinfra Co's Debt-to-EBITDA falls into.



Bioinfra Co Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Bioinfra Co's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4516.153 + 4474.798) / 4093.783
=2.20

Bioinfra Co's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(4432.208 + 4310.385) / -875.22
=-9.99

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2024) EBITDA data.


Bioinfra Co  (XKRX:199730) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Bioinfra Co Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Bioinfra Co's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Bioinfra Co Business Description

Traded in Other Exchanges
N/A
Address
120 Heungdeokjungang-ro, 4th and 5th Floors, Giheung-gu, Yongin-si, Gyeonggi-do, KOR, 16950
Bioinfra Co Ltd is engaged in the research and experimental development on medical sciences and pharmacy.

Bioinfra Co Headlines

No Headlines